Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.72 |
| ▸ | NAALAD2 | Q9Y3Q0 | 9/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946585 | 0.95 | ALB (0.66) | ALBNAALAD2FTOFOLH1MMP14 | |
| SCHEMBL13286293 | 0.84 | ALB (1.00) | ALBNAALAD2FTO | |
| SCHEMBL12923085 | 0.83 | ALB (0.51) | ALBNAALAD2FTOMMP14NR1H2 | |
| SCHEMBL12946728 | 0.81 | ALB (0.81) | ALBNAALAD2FTOFOLH1 | |
| SCHEMBL12914871 | 0.80 | ALB (0.67) | ALBNAALAD2FTOMMP14 | |
| SCHEMBL14769921 | 0.79 | ALB (0.65) | ALBNAALAD2FTOFOLH1MMP14 | |
| SCHEMBL25660795 | 0.79 | ALB (0.65) | ALBNAALAD2FTOFOLH1 | |
| SCHEMBL12923086 | 0.78 | ALB (0.46) | ALBNAALAD2FTOMMP14NR1H2 | |
| SCHEMBL14295942 | 0.78 | ALB (0.64) | ALBNAALAD2FTOFOLH1MMP14 | |
| SCHEMBL917141 | 0.77 | ALB (0.58) | ALBNAALAD2FTOMMP14JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014216-A1 | Drug Transfer Based on Coenzyme A and Acyl Carrier Protein | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | TSPO, MPI, ABCB1 | ALB 1457/4885NAALAD2 129/4885FTO 1922/4885 |
| US-20110014216-A1 | Drug Transfer Based on Coenzyme A and Acyl Carrier Protein | COASY, ACAT2, ACAT1 | ALB 672/4885NAALAD2 1101/4885FTO 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.